Polycythemia differential diagnosis: Difference between revisions

	Polycythemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Polycythemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography or Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Polycythemia differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Polycythemia differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Polycythemia differential diagnosis
CDC on Polycythemia differential diagnosis
Polycythemia differential diagnosis in the news
Blogs on Polycythemia differential diagnosis
Directions to Hospitals Treating Polycythemia
Risk calculators and risk factors for Polycythemia differential diagnosis

← Older edit Newer edit →

VisualWikitext

Revision as of 17:18, 22 August 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Differential Diagnosis of Polycythemia

Polycythemia must be differentiated from a variety of other conditions.^[1]^[2]^[3]

Category	Disease	Etiology	Mutation	Clinical manifestations														Laboratory findings						Gold standard disgnosis	Associated findings
				Demography	Symptoms						Signs							CBC				EPO level	PBS
				Demography	Fatigue	Headache	Shortness of breath	Bleeding	Pain	Other symptoms	Appearance	SaO2	Fever	BP	Tenderness	Splenomegaly	Other signs	Hb	RBC	WBC	Plt	EPO level	PBS
Mutational causes	Polycythemia vera (PV)^[4]	Autonomous erythrocyte production	JAK2 mutation > 95%	Mean age >60 years old	+	+	+	±	Erythromelagia Chest pain	Stroke-like symptoms Pruritis Dizziness Visual disturbance	Facial plethora	Nl	−	↑	Painful erythema	+	Lymphadenopathy	↑	↑ RBC mass	Nl to ↑	Nl to ↑	↓	Elevated normochromic, normocytic RBCs Thrombocytosis Rarely immature cells Leukoerythroblastic picture	WHO criteria for PV	Stroke Venous thrombosis Myelofibrosis Acute leukemia
	Chuvash polycythemia^[5]	Hypoxia-sensing disorder	VHL mutation	Russia, Italy <40 years old	+	+	+	±	Arthralgia	Pruritis Dizziness	Facial plethora	↓	−	↑	Painful erythema	+	Lymphadenopathy	↑	↑	Nl	Nl	↑	Elevated normochromic, normocytic RBCs	Molecular genetic testing	Multiple thrombotic events
	Hereditary methemoglobinemia^[6]	Cytochrome b5 reductase deficiency Hemoglobin M disease	Mutations in globin gene	Infants	±	±	±	−	−	−	Cyanosis	Inaccurately Nl	-	Nl	−	−	Altered mental status	↑	↑	Nl	Nl	Nl	NA	RBC enzyme activity + DNA analysis	Usually asymptomatic
	Primary familial and congenital polycythemia^[7]	Autosomal dominant inheritance	EPOR mutation	Very rare	+	+	±	−	−	−	Facial plethora	Nl	-	Nl to ↑	−	−	Altered mental status	↑	↑	Nl	Nl	Nl to ↓	NA	Isolated erythrocytosis + genetic testing	Mild manifestations of hyperviscosity
Category	Disease	Etiology	Mutation	Demography	Fatigue	Headache	Shortness of breath	Bleeding	Pain	Other symptoms	Appearance	SaO2	Fever	BP	Tenderness	Splenomegaly	Other signs	Hb	RBC	WBC	Plt	EPO level	PBS	Gold standard diagnosis	Associated findings
Iatrogenic causes	Smoking^[8]^[9]	Reduced plasma volume Accelerated erythropoiesis	−	Any	−	−	+	−	−	−	Cyanosis	↓	−	Nl	−	−	−	↑	Nl	Nl to ↑	Nl to ↑	Nl to ↓	NA	Clinical manifestation	NA
	Chronic exposure to carbon monoxide^[10]	Occupational exposure	−	Miners, fire fighters	+	+	+	−	−	Dizziness Altered cognition	Cyanosis, flushed cheeks	Nl	−	Nl	−	−	−	↑	↑	Nl	Nl	Nl to ↓	NA	Blood level of carboxyhemoglobin	Concomitant cyanide exposure
	Diuretics^[11]	Reduced plasma volume	-	Any	-	-	-	-	-	Dizziness	Nl	Nl	-	Nl to ↓	-	-	-	↑	Nl	Nl	Nl	Nl to ↓	NA	Clinical manifestation	NA
	Use of androgens or anabolic steroids^[12]	Reduced plasma volume Accelerated erythropoiesis	-	Athletes	-	+	-	-	-	-	Muscular	Nl	-	Nl to ↑	-	-	-	↑	↑	Nl	Nl	↓	NA	Clinical manifestation	Hypogonadism
	Self-injection of erythropoietin	Reduced plasma volume Accelerated erythropoiesis	-	Athletes	-	+	-	-	-	-	Muscular	Nl	-	Nl to ↑	-	-	-	↑	↑	Nl	Nl	↓	NA	Clinical manifestation	Hypogonadism
Secondary causes	Secondary polycythemia due to hypoxemia	Chronic lung disease Right-to-left cardiac shunts Sleep apnea High altitude	−	Depends on etiology	+	+	+	−	Depends on etiology	Shortness of breath	Cyanosis	↓	−	Nl to ↑	−	−	Crackles Tachypnea Tachycardia	↑	↑	Nl	Nl	↑	NA	Clinical manifestation + imaging	Variable manifestations given the diverse etiologies
	Secondary polycythemia due to erythropoietin producing tumor	Renal cell carcinoma Hepatocellular carcinoma Cerebellar hemangioblastoma Pheochromocytoma Uterine fibroids	−	Depends on etiology	+	−	−	−	Depends on etiology	Depends on etiology	Chronically ill	Nl	±	Nl to ↑	±	±	Hepatomegaly Bruising	↑/↓	↑/↓	Nl	↑	↑	NA	Clinical manifestation + imaging	Variable manifestations given the diverse etiologies
	Hereditary hemorrhagic telangiectasia	Pulmonary arteriovenous malformations																↑/↓	↑/↓
Category	Disease	Etiology	Mutation	Demography	Fatigue	Headache	Shortness of breath	Bleeding	Pain	Other symptoms	Appearance	SaO2	Fever	BP	Tenderness	Splenomegaly	Other signs	Hb	RBC	WBC	Plt	EPO level	PBS	Gold standard diagnosis	Associated findings

References

↑ Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.
↑ Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.
↑ Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.
↑ Stein, Brady L.; Oh, Stephen T.; Berenzon, Dmitriy; Hobbs, Gabriela S.; Kremyanskaya, Marina; Rampal, Raajit K.; Abboud, Camille N.; Adler, Kenneth; Heaney, Mark L.; Jabbour, Elias J.; Komrokji, Rami S.; Moliterno, Alison R.; Ritchie, Ellen K.; Rice, Lawrence; Mascarenhas, John; Hoffman, Ronald (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F". Journal of Clinical Oncology. 33 (33): 3953–3960. doi:10.1200/JCO.2015.61.6474. ISSN 0732-183X.
↑ Zhou, Amy W.; Knoche, Eric M.; Engle, Elizabeth K.; Ban-Hoefen, Makiko; Kaiwar, Charu; Oh, Stephen T. (2016). "Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia". New England Journal of Medicine. 375 (5): 494–496. doi:10.1056/NEJMc1600337. ISSN 0028-4793.
↑ Da-Silva SS, Sajan IS, Underwood JP (August 2003). "Congenital methemoglobinemia: a rare cause of cyanosis in the newborn--a case report". Pediatrics. 112 (2): e158–61. PMID 12897322.
↑ Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/
↑ Hasselbalch, Hans Carl (2015). "Smoking as a contributing factor for development of polycythemia vera and related neoplasms". Leukemia Research. 39 (11): 1137–1145. doi:10.1016/j.leukres.2015.09.002. ISSN 0145-2126.
↑ Malenica, Maja; Prnjavorac, Besim; Bego, Tamer; Dujic, Tanja; Semiz, Sabina; Skrbo, Selma; Gusic, Amar; Hadzic, Ajla; Causevic, Adlija (2017). "Effect of Cigarette Smoking on Haematological Parameters in Healthy Population". Medical Archives. 71 (2): 132. doi:10.5455/medarh.2017.71.132-136. ISSN 0350-199X.
↑ Wu, P. E.; Juurlink, D. N. (2014). "Carbon monoxide poisoning". Canadian Medical Association Journal. 186 (8): 611–611. doi:10.1503/cmaj.130972. ISSN 0820-3946.
↑ Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF (March 1988). "Erythrocythemia following renal transplantation: influence of diuretic therapy". Clin. Nephrol. 29 (3): 119–23. PMID 3282731.
↑ Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM (December 1991). "Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence". J. Urol. 146 (6): 1566–70. PMID 1942342.

[pmid25611051-1] Tefferi A, Barbui T (2015). "Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management". Am J Hematol. 90 (2): 162–73. doi:10.1002/ajh.23895. PMID 25611051.

[pmid16879015-2] Sanchez S, Ewton A (2006). "Essential thrombocythemia: a review of diagnostic and pathologic features". Arch Pathol Lab Med. 130 (8): 1144–50. doi:10.1043/1543-2165(2006)130[1144:ET]2.0.CO;2. PMID 16879015.

[pmid24729196-3] Jabbour E, Kantarjian H (2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am J Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.

[SteinOh2015-4] Stein, Brady L.; Oh, Stephen T.; Berenzon, Dmitriy; Hobbs, Gabriela S.; Kremyanskaya, Marina; Rampal, Raajit K.; Abboud, Camille N.; Adler, Kenneth; Heaney, Mark L.; Jabbour, Elias J.; Komrokji, Rami S.; Moliterno, Alison R.; Ritchie, Ellen K.; Rice, Lawrence; Mascarenhas, John; Hoffman, Ronald (2015). "Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery ofJAK2 V617F". Journal of Clinical Oncology. 33 (33): 3953–3960. doi:10.1200/JCO.2015.61.6474. ISSN 0732-183X.

[ZhouKnoche2016-5] Zhou, Amy W.; Knoche, Eric M.; Engle, Elizabeth K.; Ban-Hoefen, Makiko; Kaiwar, Charu; Oh, Stephen T. (2016). "Clinical Improvement with JAK2 Inhibition in Chuvash Polycythemia". New England Journal of Medicine. 375 (5): 494–496. doi:10.1056/NEJMc1600337. ISSN 0028-4793.

[pmid12897322-6] Da-Silva SS, Sajan IS, Underwood JP (August 2003). "Congenital methemoglobinemia: a rare cause of cyanosis in the newborn--a case report". Pediatrics. 112 (2): e158–61. PMID 12897322.

[7] Bento C, McMullin MF, Percy M, et al. Primary Familial and Congenital Polycythemia. 2016 Nov 10. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK395975/

[Hasselbalch2015-8] Hasselbalch, Hans Carl (2015). "Smoking as a contributing factor for development of polycythemia vera and related neoplasms". Leukemia Research. 39 (11): 1137–1145. doi:10.1016/j.leukres.2015.09.002. ISSN 0145-2126.

[MalenicaPrnjavorac2017-9] Malenica, Maja; Prnjavorac, Besim; Bego, Tamer; Dujic, Tanja; Semiz, Sabina; Skrbo, Selma; Gusic, Amar; Hadzic, Ajla; Causevic, Adlija (2017). "Effect of Cigarette Smoking on Haematological Parameters in Healthy Population". Medical Archives. 71 (2): 132. doi:10.5455/medarh.2017.71.132-136. ISSN 0350-199X.

[WuJuurlink2014-10] Wu, P. E.; Juurlink, D. N. (2014). "Carbon monoxide poisoning". Canadian Medical Association Journal. 186 (8): 611–611. doi:10.1503/cmaj.130972. ISSN 0820-3946.

[pmid3282731-11] Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF (March 1988). "Erythrocythemia following renal transplantation: influence of diuretic therapy". Clin. Nephrol. 29 (3): 119–23. PMID 3282731.

[pmid1942342-12] Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM (December 1991). "Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence". J. Urol. 146 (6): 1566–70. PMID 1942342.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

@@ Line 207: / Line 207: @@
 |-
 ! rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Iatrogenic causes
-! align="center" style="background:#DCDCDC;" |Smoking<ref name="Hasselbalch2015">{{cite journal|last1=Hasselbalch|first1=Hans Carl|title=Smoking as a contributing factor for development of polycythemia vera and related neoplasms|journal=Leukemia Research|volume=39|issue=11|year=2015|pages=1137–1145|issn=01452126|doi=10.1016/j.leukres.2015.09.002}}</ref><ref name="MalenicaPrnjavorac2017">{{cite journal|last1=Malenica|first1=Maja|last2=Prnjavorac|first2=Besim|last3=Bego|first3=Tamer|last4=Dujic|first4=Tanja|last5=Semiz|first5=Sabina|last6=Skrbo|first6=Selma|last7=Gusic|first7=Amar|last8=Hadzic|first8=Ajla|last9=Causevic|first9=Adlija|title=Effect of Cigarette Smoking on Haematological Parameters in Healthy Population|journal=Medical Archives|volume=71|issue=2|year=2017|pages=132|issn=0350-199X|doi=10.5455/medarh.2017.71.132-136}}</ref>
+! align="center" style="background:#DCDCDC;" |[[Smoking]]<ref name="Hasselbalch2015">{{cite journal|last1=Hasselbalch|first1=Hans Carl|title=Smoking as a contributing factor for development of polycythemia vera and related neoplasms|journal=Leukemia Research|volume=39|issue=11|year=2015|pages=1137–1145|issn=01452126|doi=10.1016/j.leukres.2015.09.002}}</ref><ref name="MalenicaPrnjavorac2017">{{cite journal|last1=Malenica|first1=Maja|last2=Prnjavorac|first2=Besim|last3=Bego|first3=Tamer|last4=Dujic|first4=Tanja|last5=Semiz|first5=Sabina|last6=Skrbo|first6=Selma|last7=Gusic|first7=Amar|last8=Hadzic|first8=Ajla|last9=Causevic|first9=Adlija|title=Effect of Cigarette Smoking on Haematological Parameters in Healthy Population|journal=Medical Archives|volume=71|issue=2|year=2017|pages=132|issn=0350-199X|doi=10.5455/medarh.2017.71.132-136}}</ref>
 | align="left" style="background:#F5F5F5;" |
@@ Line 228: / Line 228: @@
 | align="center" style="background:#F5F5F5;" | −
 | align="center" style="background:#F5F5F5;" | ↑
-| align="center" style="background:#F5F5F5;" | ↑
+| align="center" style="background:#F5F5F5;" |Nl
 | align="center" style="background:#F5F5F5;" | Nl to ↑
 | align="center" style="background:#F5F5F5;" | Nl to ↑
@@ Line 236: / Line 236: @@
 | align="center" style="background:#F5F5F5;" | NA
 |-
-! align="center" style="background:#DCDCDC;" |Chronic exposure to carbon monoxide<ref name="WuJuurlink2014">{{cite journal|last1=Wu|first1=P. E.|last2=Juurlink|first2=D. N.|title=Carbon monoxide poisoning|journal=Canadian Medical Association Journal|volume=186|issue=8|year=2014|pages=611–611|issn=0820-3946|doi=10.1503/cmaj.130972}}</ref>
+! align="center" style="background:#DCDCDC;" |[[Carbon monoxide poisoning|Chronic exposure to carbon monoxide]]<ref name="WuJuurlink2014">{{cite journal|last1=Wu|first1=P. E.|last2=Juurlink|first2=D. N.|title=Carbon monoxide poisoning|journal=Canadian Medical Association Journal|volume=186|issue=8|year=2014|pages=611–611|issn=0820-3946|doi=10.1503/cmaj.130972}}</ref>
 | align="left" style="background:#F5F5F5;" |
 * Occupational exposure
@@ Line 248: / Line 248: @@
 | align="left" style="background:#F5F5F5;" |
 * Dizziness
-* Headache
 * Altered cognition
 | align="center" style="background:#F5F5F5;" | [[Cyanosis]], flushed cheeks
@@ Line 267: / Line 266: @@
 * Concomitant [[cyanide]] exposure
 |-
-! align="center" style="background:#DCDCDC;" |Diuretics
+! align="center" style="background:#DCDCDC;" |[[Diuretic|Diuretics]]<ref name="pmid3282731">{{cite journal |vauthors=Pollak R, Maddux MS, Cohan J, Jacobsson PK, Mozes MF |title=Erythrocythemia following renal transplantation: influence of diuretic therapy |journal=Clin. Nephrol. |volume=29 |issue=3 |pages=119–23 |date=March 1988 |pmid=3282731 |doi= |url=}}</ref>
 | align="center" style="background:#F5F5F5;" |
-| align="center" style="background:#F5F5F5;" |
+* Reduced plasma volume
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |Any
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
 | align="center" style="background:#F5F5F5;" |
-| align="center" style="background:#F5F5F5;" |
+* Dizziness
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl to ↓
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl to ↓
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | NA
+| align="center" style="background:#F5F5F5;" | Clinical manifestation
+| align="center" style="background:#F5F5F5;" | NA
 |-
-! align="center" style="background:#DCDCDC;" |Use of androgens or anabolic steroids
+! align="center" style="background:#DCDCDC;" |Use of [[Androgen|androgens]] or [[Anabolic steroid|anabolic steroids]]<ref name="pmid1942342">{{cite journal |vauthors=Krauss DJ, Taub HA, Lantinga LJ, Dunsky MH, Kelly CM |title=Risks of blood volume changes in hypogonadal men treated with testosterone enanthate for erectile impotence |journal=J. Urol. |volume=146 |issue=6 |pages=1566–70 |date=December 1991 |pmid=1942342 |doi= |url=}}</ref>
 | align="left" style="background:#F5F5F5;" |
-* Doping in athletes
+* Reduced plasma volume
-| align="center" style="background:#F5F5F5;" |
+* Accelerated [[erythropoiesis]]
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Athletes
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | +
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Muscular
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |Nl to ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↓
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |NA
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Clinical manifestation
+| align="center" style="background:#F5F5F5;" |
+* [[Hypogonadism]]
 |-
-! align="center" style="background:#DCDCDC;" |Self-injection of erythropoietin
+! align="center" style="background:#DCDCDC;" |Self-injection of [[erythropoietin]]
 | align="left" style="background:#F5F5F5;" |
-* Doping in athletes
+* Reduced plasma volume
-| align="center" style="background:#F5F5F5;" |
+* Accelerated [[erythropoiesis]]
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Athletes
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | +
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Muscular
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |Nl to ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | -
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↑
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Nl
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | ↓
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" |NA
-| align="center" style="background:#F5F5F5;" |
+| align="center" style="background:#F5F5F5;" | Clinical manifestation
+| align="center" style="background:#F5F5F5;" |
+* [[Hypogonadism]]
 |-
 ! rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Secondary causes
-! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to hypoxemia
+! align="center" style="background:#DCDCDC;" |Secondary polycythemia due to [[hypoxemia]]
 | align="left" style="background:#F5F5F5;" |
 * Chronic lung disease
@@ Line 418: / Line 423: @@
 * Variable manifestations given the diverse etiologies
 |-
-! align="center" style="background:#DCDCDC;" |Hereditary hemorrhagic telangiectasia
+! align="center" style="background:#DCDCDC;" |[[Hereditary hemorrhagic telangiectasia]]
 | align="center" style="background:#F5F5F5;" |Pulmonary arteriovenous malformations
 | align="center" style="background:#F5F5F5;" |

Polycythemia differential diagnosis: Difference between revisions

Revision as of 17:18, 22 August 2018

Overview

Differential Diagnosis of Polycythemia

References

Navigation menu

Search